Literature DB >> 2577296

Pharmacology of acute effort angina.

L H Opie1.   

Abstract

From the pharmacologic point of view, each of the major types of antianginal agents--calcium antagonists, beta-blockers, and nitrates--seem to act at least in part by an improvement of the myocardial blood supply. The recently elucidated mechanism of action of nitrates, acting on a common pathway with the endothelium-derived relaxation factor (EDRF), suggests an important role for guanylate cyclase and cyclic GMP in maintaining coronary artery patency in patients with coronary atheroma. The efficacy of calcium antagonists, even in effort-induced angina, is in accord with a current hypothesis that physical exercise in the presence of coronary stenosis can cause relative coronary vasoconstriction, or at the least, failure of full dilation. Therefore, calcium antagonists all act, at least in part, on the "supply" side of the supply-demand equation. Beta-adrenergic blockers appear to have as their major mode of action a reduction of heart rate, which not only reduces the oxygen demand but, through an anti-ischemic effect, also appears to improve the endocardial blood supply (in relation to the heart rate). Thus beta-blockade indirectly enhances the supply side of the equation. The intriguing situation arises whereby all three major types of antianginal compounds may also act by a common mechanism of anginal relief, namely, improvement in the coronary blood supply, in addition to the diverse mechanisms specific to each type of compound. That conclusion does not mean the the "demand" side of the equation can be ignored. Rather, the critical importance of a reduced myocardial blood supply in the production of anginal syndromes is highlighted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577296     DOI: 10.1007/bf00148470

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  96 in total

1.  Comparison of nifedipine alone with propranolol alone for stable angina pectoris including hemodynamics at rest and during exercise.

Authors:  M B Higginbotham; K G Morris; R E Coleman; F R Cobb
Journal:  Am J Cardiol       Date:  1986-05-01       Impact factor: 2.778

2.  Oral phentolamine in angina pectoris.

Authors:  L Gould; C V Reddy; R F Gomprecht
Journal:  Jpn Heart J       Date:  1973-09

3.  Comparison of metabolic and vasoconstrictor stimuli on coronary vascular resistance in man.

Authors:  G H Mudge; S Goldberg; S Gunther; T Mann; W Grossman
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

Review 4.  Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil.

Authors:  B N Singh; C Y Chew; M A Josephson; M Packer
Journal:  Am J Cardiol       Date:  1982-10       Impact factor: 2.778

5.  Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris.

Authors:  M B Leon; D R Rosing; R O Bonow; L C Lipson; S E Epstein
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

6.  "Variant" angina: one aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients.

Authors:  A Maseri; S Severi; M D Nes; A L'Abbate; S Chierchia; M Marzilli; A M Ballestra; O Parodi; A Biagini; A Distante
Journal:  Am J Cardiol       Date:  1978-12       Impact factor: 2.778

7.  Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced angina pectoris.

Authors:  D Ardissino; S De Servi; J A Salerno; G Specchia; M Previtali; A Mussini; P Bobba
Journal:  Eur Heart J       Date:  1983-12       Impact factor: 29.983

8.  Effect of changes in ventricular relaxation on early diastolic coronary blood flow in canine hearts.

Authors:  L J Domalik-Wawrzynski; W J Powell; L Guerrero; I Palacios
Journal:  Circ Res       Date:  1987-11       Impact factor: 17.367

Review 9.  Role of calcium channel blockers in experimental exercise-induced ischemia.

Authors:  E Thaulow; B D Guth; J Ross
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

10.  Nifedipine prevents sympathetic vasoconstriction distal to severe coronary stenoses.

Authors:  G Heusch; A Deussen
Journal:  J Cardiovasc Pharmacol       Date:  1984 May-Jun       Impact factor: 3.105

View more
  3 in total

1.  Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations.

Authors:  O Pérez; P Gay; L Franqueza; R Carrón; C Valenzuela; E Delpón; J Tamargo
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

2.  Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

Authors:  C Thollon; C Cambarrat; J Vian; J F Prost; J L Peglion; J P Vilaine
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

3.  Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.

Authors:  Rebecca A Capel; Neil Herring; Manish Kalla; Arash Yavari; Gary R Mirams; Gillian Douglas; Gil Bub; Keith Channon; David J Paterson; Derek A Terrar; Rebecca-Ann B Burton
Journal:  Heart Rhythm       Date:  2015-05-27       Impact factor: 6.343

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.